Current state of biomarkers in ovarian cancer prognosis.
Publication/Presentation Date
1-1-2015
Abstract
High-grade serous ovarian cancer remains one of the most lethal malignancies in women. Despite recent advances in surgical and pharmaceutical therapies, survival rates remain poor. A major impediment in management of this disease, that continues to contribute to poor overall survival rates, is resistance to standard carboplatin-paclitaxel combination chemotherapies. In addition to tumor cell intrinsic mechanisms leading to drug resistance, there is increasing awareness of the crucial role of the tumor microenvironment in mediating natural immune defense mechanisms and selective pressures that appear to facilitate chemotherapy sensitivity. We provide an overview of some of the promising new genetic and immunological biomarkers in ovarian cancer and discuss their biology and their likely clinical utility in future ovarian cancer management.
Volume
11
Issue
23
First Page
3187
Last Page
3195
ISSN
1744-8301
Published In/Presented At
Au, K. K., Josahkian, J. A., Francis, J. A., Squire, J. A., & Koti, M. (2015). Current state of biomarkers in ovarian cancer prognosis. Future oncology (London, England), 11(23), 3187–3195. https://doi.org/10.2217/fon.15.251
Disciplines
Medicine and Health Sciences
PubMedID
26551891
Department(s)
Department of Medicine, Section of Palliative Medicine and Hospice, Fellows and Residents
Document Type
Article